News
Testing RAS Gene Mutations in Patients with Colorectal Cancer
Correct identification of the RAS oncogene variant is crucial for deciding the treatment of patients with colorectal cancer. Information on the prevalence of individual RAS gene mutations varies significantly in the literature, which may be due to different testing methods. The authors of the presented analysis focused on how the approach to testing RAS variants has evolved over time in Europe.
Reimbursement vs. Indication: Are They Clashing in Alzheimer's Disease?
Data from clinical trials and recommended procedures do not always align with insurance…
Does Dosage Frequency Matter for Adherence to Anticholinergic Treatment in Patients with COPD?
A study by Spanish authors compared the adherence of patients with chronic obstructive pulmonary…
Potential, Benefits and Proper Use of Probiotics in the Treatment of Acute Gastroenteritis in Children
Clinical studies and experiences from clinical practice have shown the benefits of administering…
L. reuteri DSM 17938 in Infant Nutrition and Its Impact on the Gut Microbiota of Infants Born by Cesarean Section
The work of the Swiss-Greek team published in the Journal of Pediatric Gastroenterology and…
Characteristics of Chronic Wounds Related to Itching During Healing
Itching of wounds during healing is associated with larger wound size, more extensive tissue swelling,...
Omalizumab and Treatment of Severe Refractory Asthma in Pregnant Women
Omalizumab is commonly recommended for the treatment of severe refractory asthma. A special group…
Combined Treatment of Chronic Lymphocytic Leukemia in Frail Patients – Results from Real-World Clinical Practice
Treatment of older patients and those with chronic lymphocytic leukemia (CLL) who are not in good…
Targeted Therapy for DLBCL Patients Who Cannot Undergo Bone Marrow Transplant
An international team of hemato-oncologists has been involved in testing polatuzumab vedotin in…
Comparison of Efficacy of Ixekizumab and Adalimumab in Patients with Psoriatic Arthritis and Moderate to Severe Psoriasis
Ixekizumab, a humanized monoclonal antibody against interleukin 17A (IL-17A), is approved in the…